"These results show an exciting, new approach to the treatment of large, solid tumors," said Dr. Philip Thorpe, Ph.D.,
 a principle investigator in the study and the Serena Simmons Distinguished Chair of Cancer Immunopharmacology at
 the University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Thorpe, a pioneer in the field of vascular
 targeting and scientific founder of Peregrine Pharmaceuticals, added "Because vascular targeting agents are highly
 specific and anchor to endothelial cells in contact with blood, considerably less drug is needed to achieve a
 therapeutic effect, thus providing a less toxic, yet highly effective therapy for solid tumor treatment." Peregrine
 Pharmaceuticals recently announced that it will be acquired by Techniclone Corporation (NASDAQ: TCLN), a
 cancer therapeutic company that is also pioneering treatment of solid tumors.